Minerva Neurosciences (NERV) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 4:01 PM EDT- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - - Company advancing CNS pipeline with MIN-117 and MIN-301 - - Management to host conference call today at 4:30 p.m. ET -
WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases... More
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 4:01 PM EDT- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - - Company advancing CNS pipeline with MIN-117 and MIN-301 - - Management to host conference call today at 4:30 p.m. ET -
WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases... More
